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The generation of neuronal cells from stem cells obtained from adult bone marrow is of signiﬁcant clinical interest in order to
design new cell therapy protocols for several neurological disorders. The recent identiﬁcation in adult bone marrow of stem cells
derived from the neural crests (NCSCs) might explain the neuronal phenotypic plasticity shown by bone marrow cells. However,
little information is available about the nature of these cells compared to mesenchymal stem cells (MSCs). In this paper, we will
review all information available concerning NCSC from adult tissues and their possible use in regenerative medicine. Moreover,
as multiple recent studies showed the beneﬁcial eﬀect of bone marrow stromal cells in neurodegenerative diseases, we will discuss
which stem cells isolated from adult bone marrow should be more suitable for cell replacement therapy.
1.Introduction
Neurodegenerative disease is a generic term used for a wide
range of acute and chronic conditions whose etiology is un-
knownsuchasParkinson’sdisease,Huntington’sdisease,am-
yotrophiclateralsclerosis(ALS),Alzheimer’sdisease,butalso
now for other neurological diseases whose etiology is better
known but which are also concerned by a chronic lost of
neuronsandglialcellssuchasmultiplesclerosis(MS),stroke,
and spinal cord injury. Although the adult brain contains
small numbers of stem cells in restricted areas, the central
nervous system exhibits limited capacity of regenerating lost
tissue.Therefore,cellreplacementtherapiesoflesionedbrain
have provided the basis for the development of potentially
powerful new therapeutic strategies for a broad spectrum
of human neurological diseases. However, the paucity of
suitable cell types for cell replacement therapy in patients
suﬀering from neurological disorders has hampered the
development of this promising therapeutic approach.
Stemcellsareclassicallydeﬁnedascellsthathavetheabil-
itytorenewthemselvescontinuouslyandpossesspluripotent
or multipotent ability to diﬀerentiate into many cell types.
Beside the germ stem cells devoted to give rise to ovocytes
or spermatozoids, those cells can be classiﬁed in three sub-
groups: embryonic stem cells (ES), induced pluripotent stem
cells (iPS), and somatic stem cells (Figure 1). ES cells are
derived from the inner mass of blastocyst and are considered
as pluripotent stem cells as these cells can give rise to various
mature cells from the three germ layers. iPS cells are also
pluripotent stem cells; however, those cells derived from
adult somatic cells such as skin ﬁbroblasts are genetically
modiﬁed by introduction of four embryogenesis-related
genes [1, 2]. Finally, tissue-speciﬁc stem cells known as
somatic or adult stem cells are more restricted stem cells
(multipotent stem cells) and are isolated from various fetal
or adult tissues (i.e., hematopoietic stem cells, bone marrow
mesenchymal stem cells, adipose tissue-derived stem cells,
amniotic ﬂuid stem cells, neural stem cells, and so forth) [3].
In recent years, neurons and glial cells have been success-
fully generated from stem cells such as embryonic stem cells
[4],iPS[5],mesenchymalstemcells(MSCs)[6,7],andadult
neural stem cells [8], and extensive eﬀorts by investigators
to develop stem cell-based brain transplantation therapies
have been carried out. Over the last decade, convincing2 Journal of Biomedicine and Biotechnology
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Figure 1:Stemcelltypeandorigin.Besidegermstemcells,threegroupofstemcellscanbedeﬁnedaccordingtotheirdiﬀerentiatingabilities:
(a) pluripotent embryonic stem cells (ES), (b) induced pluripotent stem cells (iPS), and (c) multipotent fetal or adult somatic stem cells.
evidence has emerged of the capability of various stem cell
populations to induce regeneration in animal models of
Parkinson’s disease (PD), Huntington’s disease, Alzheimer’s
disease (AD), multiple sclerosis, or cerebral ischemia [9].
Some of the studies have already been carried out to
clinical trials. In example, in the case of Parkinson’s disease,
transplantation of fetalventralmesencephalontissue directly
into the brains of PD patients has been done in a few
centers with varying results [10–12], and it appeared that
using fetal ventral mesencephalon tissue raised numerous
problems from ethical issues to heterogeneity and relative
scarcity of tissue [13] suggesting that other stem cells (like
adult somatic stem cells) may be more suitable for such a
therapy. Likewise, ES cells have also been grafted in patients
with injured spinal cord, as USA Federal Regulators have
cleared the way for the ﬁrst human trials of human ES cellJournal of Biomedicine and Biotechnology 3
Table 1: Maturation steps of bone marrow derived neuron-like cells.
Maturation of BMDN 5 Days in vitro 8D a y sin vitro 12 Days in vitro
Neurotransmitter sensitivities GABA, glycine, glutamate GABA, glycine, glutamate GABA, glycine, glutamate
Potassic voltage-gated channels +++ +++ +++
Sodic voltage-gated channels − +++ +++
Action potentials − +++ +++
Trains of action potentials −−−
Synaptic activities −−−
Membrane potential (mV) −37 ±3 −50,3 ±2 −57,7 ±2,3
research, authorizing researchers to test whether those cells
are safe or not [14]. It is still too early to know the eﬀect of
ES cells on patient recovery; however, several concerns have
been previously raised on animal models as ES cells induced
teratocarcinomas and some exploratory clinical trials are
conﬁrming the animal studies [15].
In thispaper , we will review our results concerning iden-
tiﬁcation and characterization of neural crest stem cells
(NCSCs) in adult bone marrow as a potential source for cel-
lular therapy in neurological disorders. We will also discuss
whatarethemainquestionsthatremainpending concerning
the use of those cells in cellular therapy protocols for neuro-
logical disorders.
2.SomaticStemCellsIsolatedfrom
Adult Bone Marrow
The postnatal bone marrow has traditionally been seen as
an organ composed of two main systems rooted in distinct
lineages—the hematopoietic tissue and the associated sup-
porting stroma. The evidence pointing to a putative stem cell
upstream of the diverse lineages and cell phenotypes com-
prising the bone marrow stromal system has made marrow
the only known organ in which two (or more) separate and
distinct stem cells and dependent tissue systems not only
coexist but functionally cooperate, deﬁning hematopoietic
stem cells (HSCs) and mesenchymal stem cells (MSCs) [16].
MSCs were ﬁrst isolated from the bone marrow (BM-
MSC) stem cell niche. More recently, extensive research has
revealed that cells with morphological and functional char-
acteristics similar to BM-MSC can be identiﬁed in a large
number of organs or tissues including adipose tissue and
peripheral blood. Despite having diﬀerent origins, these
MSC populations maintain cell biological properties typi-
cally associated with stem cells. These include continuous
cell cycle progression for self-renewal and the potential to
diﬀerentiate into highly specialized cell types of the meso-
dermal phenotype including chondroblast, osteoblast, and
adipocyte lineages. Interestingly, BM-MSCs have also been
reported to be inducible via the ectodermal or endodermal
germline, demonstrating the expression of neuron-like fac-
tors,insulin production , or hepatic lineage-associated genes,
respectively. In addition to these general stem cell properties,
the International Society for Cellular Therapy proposed a
more speciﬁc panel of markers for the characterization of
MSC. Due to the failure to identify a certain unique MSC
cell-surface molecule, a set of minimal criteria for MSC was
recommended, which includes the capability of adherence to
plastic surfaces and the expression of the cell surface markers
CD44, CD73, CD90, and CD105 with a concomitant absence
of CD14, CD19, CD34, CD45, and HLA-DR expression [17].
Originally analyzed because of their critical role in the
formation of the hematopoietic microenvironment (HME),
bone marrow stromal cells became interesting because of
their surprising ability to diﬀerentiate into mature neural
cell types. More recently, a third stem cell group has been
identiﬁed as originating from the neural crest, which could
explain the capacity of stromal stem cells to diﬀerentiate into
functional neurons.
3. Neural PhenotypicPlasticityof Adult Bone
Marrow Stromal Cells
Several years ago, we demonstrated that a fraction of
bone marrow stromal cells were able to diﬀerentiate into
functional neurons. Those speciﬁc cells were characterized
as nestin-positive mesenchymal stem cells [6, 7, 18]. Elec-
trophysiological analyses using the whole-cell patch-clamp
technique revealed that adult rat bone marrow stromal cells
[6, 7]w e r ea b l et od i ﬀerentiate into excitable neuron-like
cells when they were cocultivated with mouse cerebellar
granule neurons. First, we demonstrated that those cells
express several neuronal markers (NeuN and Beta-III tubu-
lin; Figure 2), an axonal marker (neuroﬁlament H and M
proteinrecognizedbythemonoclonalantibody,SMI31),and
a dendritic marker (MAP2ab). Electrophysiological record-
ings of these nestin-positive bone-marrow-derived neuron-
like cells (BMDN) were performed, and three maturation
stages were observed (Table 1).
A t4 – 6d a y so fc o c u l t u r e ,B M D Ns h o w e ds o m en e u r o -
transmitter responsiveness (GABA, glycine, serotonin, and
glutamate) and voltage-gated K+ currents inhibited by TEA
(tetraethylammonium). However, those cells did not express
functional sodium voltage-gated channels and have a high
membranepotential(Vrest)(−37.6
◦±3mV ,n = 61).During
the second week of coculture, BMDN started to display
Na+ currents reversely inhibited by TTX (tetrodotoxin) and
became able to ﬁre single spike of action potential. In
those older cocultures, the Vrest reaches a more negative
value, which was closer to the value usually measured in
neurons (7–9 days, −50.3 ± 2mV ,n = 76 and 10–15 days,
−56.7 ±2.3mV ,n = 97).4 Journal of Biomedicine and Biotechnology
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Figure 2: Neuronal marker expressed by bone marrow stromal cells. Bone marrow stromal cells were cocultivated for 5 days with GFP-
positive cerebellar granule neurons (green). Immunoﬂuorescence labeling showed that beta-III tubulin recognize by Tuj1 antibodies (red)
was expressed by about 20% of bone marrow stromal cells (GFP-negative or nongreen cells) [6, 7].
As only nestin-positive bone marrow stromal cells were
able to diﬀerentiate into functional neurons, we performed
several proteomic and transcriptomic comparisons that
pointed out several characteristics like ErbB3 and Sox10
overexpression in nestin-positive MSCs, suggesting that
these cells could actually be neural-crest-derived cells [19].
Few months later, Nogoshi et al. [20] conﬁrmed the presence
of neural-crest-derived cells in adult bone marrow.
4. Characterizationof Neural CrestStem Cells
from Adult Bone Marrow
4.1. Neural Crest Stem Cell Origin. In early vertebrate de-
velopment, the neural crest is speciﬁed in the embryonic
ectoderm at the boundary of the neural plate and the
ectoderm. Once speciﬁed, the neural crest cells undergo
a process of epithelium to mesenchyme transition (EMT)
that will confer them the ability to migrate. The EMT
involves diﬀerent molecular and cellular machineries and
implies deep changes in cell morphology and in the type
of cell surface adhesion and recognition molecules. When
the EMT is complete, they delaminate from the neural
folds/neural tube and migrate along characteristic pathways
to diﬀerentiate into a wide variety of derivates (Figure 3)
[21].
Takahashi et al. [1] was the ﬁrst to address the biological
origin of MSCs and showed that they are generated in
waves, with the neuroepithelium unexpectedly providing
the ﬁrst wave and a second wave of nonneural-derived
MSCs taking precedence in the adult [22]. Indeed, using
protocols that diﬀerentiate ES cells to mesodermal versus
neural/neural crest lineages, they demonstrated that both
lineages generated PDGFRa-positive cells (a marker for
MSC) that could make adipocytes. However, the surprise
came when they found that the neural, but not mesoder-
mal, diﬀerentiations contained MSCs that could proliferate
extensively as multipotent clones. Moreover, these MSCs
were generated from cells expressing Sox1, a deﬁnitive
marker for neuroepithelium, demonstrating their neural
origin. Thus, for ES cells, diﬀerentiation along a mesodermal
pathway did not generate MSCs, but diﬀerentiation toward a
neural/neural crest fate did.
In order to address the in vivo relevance of these ﬁnd-
ings,Takahashi et al. [1] used a transgenic mice expressing
GFP under Sox1 promoter. They then isolated the trunk
of these embryos at E9.5 (thereby excluding the cranial
neural crest, which is known to generate mesenchymal cells)
and demonstrated that Sox1-GFP-positive cells gave rise to
PDGFRa-positiveMSC.Incontrast,GFP-negative,PDGFRa-
positive cells (which expressed mesodermal markers) did not
generate MSCs, although they did make adipocytes. Thus,Journal of Biomedicine and Biotechnology 5
Neural crest cells
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Figure 3:Neurulationandneuralcrestmigration.Asneurulationproceeds,theneuralplaterollsupandtheneuralplateborderbecomesthe
neural folds. Near the time of neural tube closure (depending on the species), the neural crest cells go through an epithelial to mesenchymal
transition (EMT), delaminate from the neural folds or dorsal neural tube, and migrate along deﬁned pathways.
Table 2: Presence of neural-crest-derived cells in adult tissues.
Place Marker Animal Genotype Reference
Gut P75NTR Rat Wild type [23]
DRG Rat Wild type [24]
DRG, Whisker pad, bone, marrow EGFP Mouse P0
Wnt1-CRE/CAG-EGFP [20]
Skin Mouse Wild type [22]
Skin Lacz Mouse Wnt1-CRE/ROSA-Lacz [25]
Skin EYFP Mouse Dct-Cre/ROSA-EYFP [26]
Cornea EYFP Mouse P0
Wnt1-CRE/CAG-EGFP [27]
Carotid body EYFP Mouse GFAP promoter-EGFP [28]
justasseenwithEScells,MSCcouldbegeneratedfromtrunk
neuroepithelial cells but not from mesodermal cells in mid-
gestation embryos. These experiments demonstrated that
trunk neuroepithelium could make MSC. To demonstrate
that it actually did so, the authors made Sox1-Cre/YFP mice
in which the progeny of Sox1-positive neuroepithelial cells
were persistently labeled and conﬁrmed the presence of YFP
cells in adult bone marrow.
In parallel, using a two-component genetic system based
on Cre/lox recombination to label indelibly the entire
mouse neural crest population at the time of its formation
[29], several groups used Wnt1-Cre/R26R double transgenic
mice, in which virtually all neural crest stem cells express
β-galactosidase, to identiﬁed NCSC in various tissues.
Indeed, using this transgenic model, Sieber-Blum et al. [25]
demonstrated the presence of pluripotent neural crest stem
cells in adult follicle hairs, Wong et al. [26] demonstrated the
presence of neural crest cells in the mouse adult skin, and
Nagoshi et al. [20] conﬁrmed the presence of NCSC in adult
bone marrow (Table 2).
4.2. Self-Renewal Ability and Multipotency of Adult Bone
Marrow NCSC. To consider NCSC from adult bone mar-
row as a potential source for cellular therapy protocol, a
better characterization of those cells was mandatory. In
our study, we ﬁrst address the self-renewal ability, as ﬁrst
characteristic of stemness. Indeed, we demonstrated that
NCSCs were able to grow as spheres, which is one of the
main hallmarks of immature neural cells and proliferate
from a single cell culture (clonal culture). We then addressed6 Journal of Biomedicine and Biotechnology
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Figure 4: Multipotency of adult bone marrow NCSC. NCSC clones were subjected to diﬀerentiating protocols and were shown to be able to
diﬀerentiateintoadipocytes(OilRedOlabeling),melanocytes(L-DOPAlabeling),smoothmuscles(SMA-labeling),andosteocytes(alkaline
phosphatase activity). Moreover, when co-cultured with cerebellar granule neurons, we were able to diﬀerentiate NCSC clones into neurons
(beta-III tubulin labeling by Tuj1 monoclonal antibody) or glial cells (GFAP labeling).
the multipotency and veriﬁed if those NCSC clones were
able to diﬀerentiate into multiple mature cell types. Indeed,
we observed that NCSC were able to diﬀerentiate into
adipocytes, melanocytes, smooth muscles, osteocytes, neu-
rons, and astrocytes (Figure 4)[ 30].
4.3. Maintenance and Proliferation of Adult Bone Marrow
NCSC. Before using NCSC from adult bone marrow, we
have to face some limiting factors like the fact that NCSCs
are a minority population (less than 1%) in adult bone
marrow. As Wnt1 and BMP2 factors were described to
help for maintenance and proliferation of NCSC isolated
from embryo [31], we tested those two factors, on adult
NCSC isolated from adult bone marrow. Interestingly, we
demonstrated that Wnt1 and BMP2 were able to increase
the number of NCSCs present in bone marrow stromal cell
culture,uptofourtimeswithin2passages[30]reaching20%
of NCSC.Journal of Biomedicine and Biotechnology 7
5.In Vivo Characterizationof Neural Crest
StemCellsand/orBoneMarrowStromalCells
inNeurological Disorder Mice Models
5.1. Spinal Stroke. Among others, the spinal cord is the
collection of ﬁbers that runs from or to the brain through
the spine, carrying signals from or to the brain to or from
the rest of the body. Those signals control a person’s muscles
and enable the person to feel various sensations. The main
consequence of injuries to the spinal cord is the interference
with those signals. Those injuries are characterized as
“complete” or “incomplete”: if the injured person loses all
sensation and all ability to control the muscles below the
point of the injury, the injury is said “complete”; in the case
of an “incomplete” injury, the victim retains some ability to
feel sensations or control movement below the injured area.
Main goals in spinal cord repair include reconnecting
brain and lower spinal cord, building new circuits, re-
myelination of demyelinated axons, providing trophic sup-
port, and bridging the gap of the lesion [32]. Overcoming
myelin-associated and/or glial-scar-associated growth inhi-
bition are experimental approaches that have been most
successfully studied in in vivo experiments. Further issues
concern gray matter reconstitution and protecting neurons
and glia from secondary death [32].
In this purpose, neural crest stem cells isolated from
the bulge of hair follicle have been grafted in rat model
of spinal cord lesion [33]. Those cells survived, integrated,
and intermingled with host neurites in the lesioned spinal
cord. NCSC were nonmigratory and did not proliferate or
form tumors. Signiﬁcant subsets of grafted cells expressed
the neuron-speciﬁc beta-III tubulin, the GABAergic marker
glutamate decarboxylase 67 (GAD67), the oligodendrocyte
markersRIP,ormyelinbasicprotein(MBP)[25].Moreinter-
estingly, functional improvement was shown by two inde-
pendent approaches, spinal somatosensory-evoked poten-
tials(SpSEP)andtheSemmes-Weinsteintouchtest[34].The
strength of NSCS was fully characterized as they can exert a
combination of pertinent functions in the contused spinal
cord, including cell replacement, neuroprotection, angiog-
enesis, and modulation of scar formation. However, those
resultshaveneverbeenconﬁrmedwithhumanNCSC,which
should be the next promising step.
Similar studies were previously performed with bone
marrow stromal cells. Indeed, several researches reported the
antiproliferative, anti-inﬂammatory, and anti-apoptotic fea-
t u r e so fb o n em a r r o ws t r o m a lc e l l s[ 35]. Indeed, Zeng et al.
[36] demonstrated that BMSC seeded in a three dimensions
gelatin sponge scaﬀold and transplanted in a transected rat
spinal cord resulted in attenuation of inﬂammation, pro-
motion of angiogenesis, and reduction of cavity formation.
Those BMSCs were isolated from 10 weeks old rats and
passaged 3 to 6 times. Likewise, Xu et al. [37] demonstrated
that a co-culture of Schwann cell with BMSC had greater
eﬀectsoninjuredspinalcordrecoverythanuntreatedBMSC.
Indeed, analyses of chemokine and cytokine expression
revealed that BMSC/Schwann cell co-cultures produced far
less MCP-1 and IL-6 than BMSCs or Schwann cells cultured
alone. Transplanted BMSC may thus improve recovery in
spinal cord injured mice through immunosuppressive eﬀects
that can be enhanced by a Schwann cell coculturing step.
These results indicate that the temporary presence of BMSC
in the injured cord is suﬃcient to alter the cascade of
pathological events that normally occur after spinal cord
injury and therefore generating a microenvironment which
favours an improved recovery. In this study, BMSCs were
isolated from adult mice and used after 4 passages.
5.2. Krabbe’s Disease. Krabbe’s disease, a demyelinating dis-
order caused by mutations in the lysosomal enzyme gal-
actocerebrosidase (GALC), is a disorder of the nervous
system where cell transplantation is the only available
therapy [38]. In this leukodystrophy, apoptosis of myelin-
forming oligodendrocytes and Schwann cells is caused by
accumulation of a GALC substrate, galactosylsphingosine
(psychosine), which causes a severe demyelination of both
the peripheral (PNS) and central (CNS) nervous systems.
Eﬀective treatment of Krabbe’s disease is challenging given
the rapid decline of patients and the need to correct both the
PNS and CNS.
So far, the most eﬀective treatment for Krabbe’s patients
is hematopoietic stem cell (HSC) transplantation, which
supplies the missing enzyme to the nervous system; however,
this option showed only a mild and temporary beneﬁcial
eﬀect on peripheral nerves. As a consequence of a lack of
appropriate treatment, a recent study analyzed the therapeu-
tical properties of MSCs in such a disease [38]. The authors
demonstrated that MSCs had a multilevel mechanism of
action targeting neurons, Schwann cells, and macrophages
that coordinately promoted recovery of nerve pathology
following intravenous transplantation, demonstrating that
MSC could also be used in peripheral nervous system
pathology.
5.3. Multiple Sclerosis. Multiple sclerosis (MS) is a common
neurological disease and a major cause of disability, particu-
larly aﬀecting young adults. It is characterized by patches of
damageoccurring throughoutthe brainand spinal cordwith
loss of myelin sheaths accompanied by loss of cells that make
myelin (oligodendrocytes) [39]. In addition, we now know
that there is damage to neurons and their axons too, and that
this occurs both within these discrete patches and in tissue
between them. The cause of MS remains unknown, but an
autoimmune reaction against oligodendrocytes and myelin
is generally assumed to play a major role, and early acute
MS lesions almost invariably show prominent inﬂammation.
Eﬀorts to develop cell therapy of nervous system lesion in
MS have long been directed towards directly implanting cells
capable of replacing lost oligodendrocytes and regenerating
myelin sheaths.
To our knowledge, no experiment has been performed
to characterize the eﬀect of neural crest stem cells on the
improvement of multiple sclerosis disease; however, several
data can be collected concerning the positive eﬀect of
Schwann cells (derived from NCSCs) and of bone marrow
stromal cells.8 Journal of Biomedicine and Biotechnology
As previously described in injured spinal cord, bone
marrow stromal cells have been characterized on their
antiproliferative, anti-inﬂammatory, and antiapoptotic fea-
tures. These properties have been exploited in the eﬀective
treatment of experimental autoimmune encephalomyelitis
(EAE), an animal model of multiple sclerosis where the
inhibition of the autoimmune response resulted in a signif-
icant neuroprotection [35]. Based on recent experimental
data, a number of clinical trials have been designed for the
intravenous (IV) and/or intrathecal (ITH) administration of
B M S C si nM Sp a t i e n t s[ 40].
5.4. Parkinson’s Disease. Parkinson’s disease (PD) is a chron-
ic, progressive neurodegenerative disorder characterized by
a continuous and selective loss of dopaminergic neurons
in the substantia nigra pars compacta with a subsequent
reduction of dopamine release mainly in the striatum. This
ongoing loss of nigral dopaminergic neurons leads to clinical
diagnosismainlyduetooccurrenceofmotorsymptomssuch
as rigidity, tremor, and bradykinesia, which result from a
reduction of about 70% of striatal dopamine [41].
Levy et al. [42] analyzed the eﬀect of diﬀerentiated
human BMSC onto dopaminergic precursor on hemi-Par-
kinsonian rats, after transplantation into striatum. This
graft resulted in improvement of rat behavioral deﬁcits
quantiﬁed by apomorphine-induced rotational behavior.
The transplanted induced neuronal cells proved to be of
superior beneﬁt compared with the transplantation of naive
BMSC. Immunohistochemical analysis of grafted brains
revealed that abundant induced cells survived the grafting
procedure and some of these cells displayed dopaminergic
traits.
Similarly, authors in [43] isolated and characterized
MSCs from Parkinson’s disease (PD) patients and com-
pared them with MSCs derived from normal adult bone
marrow. These authors show that PD-derived MSCs are
similar to normal MSCs in phenotype, morphology, and
diﬀerentiation capacity. Moreover, PD-derived MSCs are
able of diﬀerentiating into neurons in a speciﬁc medium
with up to 30% having the characteristics of dopamine
cells. At last, PD-derived MSCs could inhibit T-lymphocyte
proliferation induced by mitogens. These ﬁndings indicate
that MSCs derived from PD patients’ bone marrow could be
a promising cell type for cellular therapy and somatic gene
therapy applications.
5.5. Huntington’s Disease. Huntington’s disease (HD) is
an autosomal dominant genetic disorder caused by the
expansion of polyglutamine encoded by CAG repeats in
Exon 1 of the IT15 gene encoding for Huntingtin (Htt). The
polyglutamine repeat length determines the age of onset and
the overall level of function but not the severity of the disease
[44]. Although the exact mechanism underlying HD disease
progression remains uncertain, the hallmark of this disease is
a gross atrophy of the striatum and cortex and a decrease of
GABAergic neurons [45].
One strategy for HD therapy is to enhance neuroge-
nesis, which has been studied by the administration of
stem/progenitor cells, including BMSCs. Several studies
[46] showed that BMSCs promote repair of the CNS by
creating a more favorable environment for neuroprotection
and regeneration through the secretion of various cytokines
and chemokines. Moreover, Snyder et al. [46] demonstrated
that BMSC injected into the dentate gyrus of HD mice
model increased neurogenesis and decreased atrophy of the
striatum.
5.6. Alzheimer’s Disease. Alzheimer’s disease (AD) is the
most common form of dementia, aﬀecting more than 18
million people worldwide. With increased life expectancy,
this number is expected to rise in the future. AD is character-
ized by progressive memory deﬁcits, cognitive impairment,
and personality changes associated with the degeneration of
multipleneuronaltypesandpathologicallybythepresenceof
neuritic or amyloid plaques and neuroﬁbrillary tangles [47].
Amyloid β-peptide (Aβ) appears to play a key pathogenic
role in AD, and studies have connected Aβ plaques with
the formation of intercellulartau tangles, anotherneurotoxic
feature of AD [48]. Currently, no treatment is available
to cure or prevent the neuronal cell death that results in
inevitable decline in AD patients.
The innate immune system is the vital ﬁrst line of
defense against a wide range of pathogens and tissue injuries,
triggering inﬂammation through activation of microglia and
macrophages. Many studies have shown that microglia are
attracted to and surround senile plaques both in human
AD samples and in rodent transgenic models that develop
AD-related disease [49]. In this context, Lee et al. [50]
demonstrated that treated APP/PS1 mice (mouse model of
AD)withBM-MSCspromotedmicroglialactivation,rescued
cognitive impairment, and reduced Aβ and tau pathology in
the mouse brain.
6. Conclusions
The NCSC is one of the most intriguing cells in the
ﬁeld of regenerative medicine, because it is easily har-
vested from various accessible peripheral tissues, which
could make autologous transplantation possible. Autologous
transplantation would avoid immunological complications
as well as the ethical concerns associated with the use of
embryonic stem cells. Of the various NCSCs, research on
skin-derived NCSC is the most advanced mainly due to their
easy isolation process. One of the critical questions for the
application of NCSC to regenerative medicine is whether
cells that are diﬀerentiated from NCSCs are functional.
Some evidence supports this [51]; however, lots of questions
remained pending. By example, a very important question
is the diﬀerentiation abilities of NCSC isolated from various
tissues: are they similar or diﬀerent?
On the other hand, even if bone marrow stromal cells
did not show a strong ability to replace lost neurons in
neurodegenerative disorders such as Parkinson’s or Hunt-
ington’s disease, their impact on inﬂammation modulation
or stimulation of endogenous cells were quite remarkable.
This impact is also illustrated by a high number of ongoingJournal of Biomedicine and Biotechnology 9
clinical trials with these cells [52]. However, the main
challenges remain the standardization of cell culture and
isolation, to meet the international rules. Indeed, more
than ever, it has been demonstrated that bone marrow
stromal cells are constituted of an heterogenous population
containing multiple stem/progenitor cell types including
mesenchymal stem cells and neural crest stem cells, among
others. Most of the studies describing the eﬀects of BMSCs
on inﬂammation modulation or stimulation of endogenous
cells were performed on low passages (<4), which mainly
contain MSC and less than 10% of NCSCs. So we could
stipulate that most of these eﬀects were probably due to
MSCs. However, in a perspective of cell therapy, a strong
characterization of the role of each cell type in neuronal
recovery seemed mandatory to establish strong and safe
protocols.
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